Background	Background	NN	0
With	With	IN	0
the	the	DT	0
publication	publication	NN	0
of	of	IN	0
the	the	DT	0
Antihypertensive	Antihypertensive	NNP	B-NP
and	and	CC	0
Lipid-Lowering	Lipid-Lowering	NNP	B-NP
Treatment	Treatment	NNP	I-NP
to	to	TO	0
prevent	prevent	VB	0
Heart	Heart	NNP	B-NP
Attack	Attack	NNP	I-NP
Trial	Trial	NNP	I-NP
(	(	-LRB-	0
ALLHAT	ALLHAT	NNP	0
)	)	-RRB-	0
,	,	,	0
the	the	DT	0
role	role	NN	0
of	of	IN	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
in	in	IN	0
the	the	DT	0
treatment	treatment	NN	0
of	of	IN	0
hypertension	hypertension	NN	0
has	has	VBZ	0
become	become	VBN	0
controversial	controversial	JJ	0
.	.	.	0
The	The	DT	0
allhat	allhat	NN	B-NP
doxazosin	doxazosin	JJ	I-NP
arm	arm	NN	I-NP
was	was	VBD	0
stopped	stopped	VBN	0
early	early	RB	0
,	,	,	0
due	due	JJ	0
to	to	TO	0
a	a	DT	0
doubling	doubling	NN	0
of	of	IN	0
the	the	DT	0
incidence	incidence	NN	0
of	of	IN	0
congestive	congestive	JJ	B-NP
heart	heart	NN	I-NP
failure	failure	NN	I-NP
in	in	IN	0
this	this	DT	0
group	group	NN	0
,	,	,	0
as	as	RB	0
compared	compared	VBN	0
to	to	TO	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
arm	arm	NN	I-NP
low-dose	low-dose	JJ	I-NP
[	[	-LRB-	0
1	1	LS	0
]	]	-RRB-	0
.	.	.	0
Prior	Prior	RB	0
to	to	TO	0
this	this	DT	0
publication	publication	NN	0
,	,	,	0
there	there	EX	0
had	had	VBD	0
been	been	VBN	0
no	no	DT	0
obvious	obvious	JJ	0
suggestion	suggestion	NN	0
of	of	IN	0
a	a	DT	0
mechanism	mechanism	NN	0
by	by	IN	0
which	which	WDT	0
peripheral	peripheral	VBD	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
in	in	IN	0
general	general	JJ	0
or	or	CC	0
doxazosin	doxazosin	NN	B-NP
in	in	IN	0
particular	particular	JJ	0
would	would	MD	0
be	be	VB	0
inferior	inferior	JJ	0
to	to	TO	0
chlorthalidone	chlorthalidone	VB	0
or	or	CC	0
would	would	MD	0
specifically	specifically	RB	0
cause	cause	VB	0
CHF	CHF	NNP	B-NP
.	.	.	0
Because	Because	IN	0
ALLHAT	ALLHAT	NNP	B-NP
is	is	VBZ	0
an	an	DT	0
active-control	active-control	JJ	B-NP
trial	trial	NN	I-NP
,	,	,	0
no	no	DT	0
inferences	inferences	NNS	0
can	can	MD	0
be	be	VB	0
made	made	VBN	0
on	on	IN	0
whether	whether	IN	0
this	this	DT	0
increased	increased	JJ	0
incidence	incidence	NN	0
of	of	IN	0
CHF	CHF	NNP	B-NP
results	results	NNS	0
from	from	IN	0
a	a	DT	0
harmful	harmful	JJ	0
effect	effect	NN	0
of	of	IN	0
doxazosin	doxazosin	NN	B-NP
,	,	,	0
a	a	DT	0
beneficial	beneficial	JJ	0
effect	effect	NN	0
of	of	IN	0
chlorthalidone	chlorthalidone	NN	B-NP
,	,	,	0
or	or	CC	0
both	both	DT	0
.	.	.	0
Nonetheless	Nonetheless	RB	0
,	,	,	0
there	there	EX	0
has	has	VBZ	0
been	been	VBN	0
a	a	DT	0
large	large	JJ	0
body	body	NN	0
of	of	IN	0
literature	literature	NN	0
dedicated	dedicated	VBN	0
to	to	TO	0
the	the	DT	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
positive	positive	JJ	I-NP
effect	effect	NN	I-NP
on	on	IN	0
surrogate	surrogate	JJ	0
endpoints	endpoints	JJ	0
such	such	JJ	0
as	as	IN	0
cholesterol	cholesterol	NN	B-NP
level	level	JJ	I-NP
and	and	CC	0
tolerability	tolerability	NN	B-NP
.	.	.	0
In	In	IN	0
light	light	NN	0
of	of	IN	0
the	the	DT	0
results	results	NNS	0
of	of	IN	0
ALLHAT	ALLHAT	NNP	B-NP
,	,	,	0
we	we	PRP	0
performed	performed	VBD	0
a	a	DT	0
review	review	NN	0
of	of	IN	0
the	the	DT	0
literature	literature	NN	0
on	on	IN	0
doxazosin	doxazosin	NN	B-NP
,	,	,	0
terazosin	terazosin	NN	B-NP
,	,	,	0
and	and	CC	0
prazosin	prazosin	NN	B-NP
.	.	.	0
Methods	Methods	NNP	0
Medline	Medline	NNP	B-NP
and	and	CC	0
the	the	DT	0
Cochrane	Cochrane	JJ	0
databases	databases	NN	0
were	were	VBD	0
used	used	VBN	0
to	to	TO	0
identify	identify	VB	0
english-language	english-language	NN	B-NP
paper	paper	NN	I-NP
on	on	IN	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
in	in	IN	0
studies	studies	NNS	0
targeting	targeting	VBG	0
cardiovascular	cardiovascular	JJ	B-NP
endpoint	endpoint	NN	I-NP
,	,	,	0
background	background	NN	B-NP
physiologic	physiologic	NN	I-NP
literature	literature	NN	I-NP
,	,	,	0
or	or	CC	0
any	any	DT	0
studies	studies	NNS	0
suggesting	suggesting	VBG	B-NP
mechanism	mechanism	NN	I-NP
leading	leading	VBG	0
to	to	TO	0
an	an	DT	0
inferior	inferior	JJ	0
performance	performance	NN	0
in	in	IN	0
cardiovascular	cardiovascular	JJ	B-NP
endpoint	endpoint	NN	I-NP
.	.	.	0
Medline	Medline	NNP	B-NP
was	was	VBD	0
searched	searched	VBN	0
from	from	IN	0
1966	1966	CD	0
to	to	TO	0
the	the	DT	0
present	present	JJ	0
with	with	IN	0
the	the	DT	0
key	key	JJ	B-NP
word	word	NN	I-NP
"doxazosin	"doxazosin	RB	0
,	,	,	0
"	"	''	0
"prazosin	"prazosin	NNP	0
,	,	,	0
"	"	''	0
"terazosin	"terazosin	NNP	0
,	,	,	0
"	"	''	0
"adrenergic	"adrenergic	NNP	0
alpha-antagonists	alpha-antagonists	NNP	0
,	,	,	0
"	"	''	0
or	or	CC	0
"alpha	"alpha	CD	0
blocker	blocker	NN	0
.	.	.	0
"	"	''	0
The	The	DT	0
search	search	NN	0
was	was	VBD	0
then	then	RB	0
limited	limited	VBN	0
to	to	TO	0
clinical	clinical	JJ	B-NP
trial	trial	NN	I-NP
that	that	WDT	0
had	had	VBD	0
"hypertension	"hypertension	NNP	0
"	"	''	0
as	as	IN	0
a	a	DT	0
key	key	JJ	B-NP
word	word	NN	I-NP
.	.	.	0
Studies	Studies	NNS	0
were	were	VBD	0
included	included	VBN	0
in	in	IN	0
our	our	PRP$	0
review	review	NN	0
if	if	IN	0
they	they	PRP	0
addressed	addressed	VBD	0
either	either	RB	0
one	one	CD	0
or	or	CC	0
a	a	DT	0
combination	combination	NN	0
of	of	IN	0
the	the	DT	0
three	three	CD	0
agents	agents	NNS	0
as	as	IN	0
the	the	DT	0
main	main	JJ	0
focus	focus	NN	0
in	in	IN	0
the	the	DT	0
context	context	NN	0
of	of	IN	0
hypertension	hypertension	JJ	B-NP
therapy	therapy	NN	I-NP
and	and	CC	0
if	if	IN	0
they	they	PRP	0
in	in	IN	0
some	some	DT	0
way	way	NN	0
addressed	addressed	VBD	0
the	the	DT	0
outcomes	outcomes	NN	0
of	of	IN	0
interest	interest	NN	0
noted	noted	VBD	0
above	above	RB	0
.	.	.	0
Relevant	Relevant	JJ	0
data	data	NNS	0
from	from	IN	0
these	these	DT	0
studies	studies	NNS	0
are	are	VBP	0
reported	reported	VBN	0
descriptively	descriptively	NN	0
.	.	.	0
Other	Other	JJ	0
relevant	relevant	JJ	0
references	references	NNS	0
were	were	VBD	0
acquired	acquired	VBN	0
from	from	IN	0
bibliographic	bibliographic	JJ	B-NP
search	search	NN	I-NP
.	.	.	0
Results	Results	NNS	0
Use	Use	NN	0
in	in	IN	0
Hypertension	Hypertension	NNP	0
and	and	CC	0
Prostatism	Prostatism	NNP	B-NP
Evidence	Evidence	NNP	I-NP
suggests	suggests	VBZ	0
that	that	IN	0
alpha-1	alpha-1	CD	B-NP
antagonist	antagonist	NN	I-NP
are	are	VBP	0
frequently	frequently	RB	0
prescribed	prescribed	VBN	0
for	for	IN	0
hypertension	hypertension	NN	0
,	,	,	0
but	but	CC	0
there	there	EX	0
are	are	VBP	0
few	few	JJ	0
published	published	JJ	0
data	data	NNS	0
concerning	concerning	VBG	0
the	the	DT	0
prevalence	prevalence	NN	0
of	of	IN	0
the	the	DT	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
routine	routine	JJ	I-NP
use	use	NN	I-NP
,	,	,	0
the	the	DT	0
prevalence	prevalence	NN	0
according	according	VBG	0
to	to	TO	0
co-morbid	co-morbid	JJ	0
conditions	conditions	NNS	0
such	such	JJ	0
as	as	IN	0
benign	benign	JJ	0
prostatic	prostatic	JJ	B-NP
hypertrophy	hypertrophy	NN	I-NP
and	and	CC	0
the	the	DT	0
usual	usual	JJ	0
duration	duration	NN	0
of	of	IN	0
therapy	therapy	NN	0
.	.	.	0
In	In	IN	0
the	the	DT	0
sixth	sixth	JJ	0
report	report	NN	0
of	of	IN	0
the	the	DT	0
Joint	Joint	NNP	0
National	National	NNP	B-NP
Committee	Committee	NNP	I-NP
on	on	IN	0
Prevention	Prevention	NNP	0
,	,	,	0
Detection	Detection	NNP	0
,	,	,	0
Evaluation	Evaluation	NNP	0
,	,	,	0
and	and	CC	0
Treatment	Treatment	NNP	0
of	of	IN	0
High	High	NNP	0
Blood	Blood	NNP	0
Pressure	Pressure	NNP	0
(	(	-LRB-	0
JNC	JNC	NNP	B-NP
VI	VI	NNP	I-NP
)	)	-RRB-	0
,	,	,	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
are	are	VBP	0
recommended	recommended	VBN	0
not	not	RB	0
only	only	RB	0
as	as	IN	0
second-line	second-line	JJ	B-NP
anti-hypertensive	anti-hypertensive	JJ	I-NP
therapy	therapy	NN	I-NP
after	after	IN	0
low-dose	low-dose	JJ	B-NP
diuretic	diuretic	NN	I-NP
and	and	CC	0
beta	beta	JJ	B-NP
blocker	blocker	NNP	I-NP
,	,	,	0
but	but	CC	0
also	also	RB	0
for	for	IN	0
specific	specific	JJ	0
indications	indications	NNS	0
such	such	JJ	0
as	as	IN	0
therapy	therapy	NN	0
in	in	IN	0
men	men	NNS	0
with	with	IN	0
hypertension	hypertension	NN	0
and	and	CC	0
prostatism	prostatism	NN	B-NP
[	[	-LRB-	0
2	2	LS	0
]	]	-RRB-	0
.	.	.	0
alpha-1	alpha-1	NN	B-NP
antagonist	antagonist	NN	I-NP
represent	represent	VBP	0
effective	effective	JJ	0
therapy	therapy	NN	0
for	for	IN	0
prostatism	prostatism	NN	B-NP
,	,	,	0
and	and	CC	0
fifty	fifty	JJ	0
percent	percent	NN	0
of	of	IN	0
men	men	NNS	0
have	have	VBP	0
histologic	histologic	JJ	B-NP
evidence	evidence	NN	I-NP
of	of	IN	0
BPH	BPH	NNP	B-NP
by	by	IN	0
60	60	CD	0
years	years	NNS	0
of	of	IN	0
age	age	NN	0
[	[	-LRB-	0
3	3	CD	0
4	4	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
National	National	NNP	B-NP
Ambulatory	Ambulatory	NNP	I-NP
Medical	Medical	NNP	I-NP
Care	Care	NNP	I-NP
Survey	Survey	NNP	I-NP
reported	reported	VBD	0
that	that	IN	0
the	the	DT	0
number	number	NN	0
of	of	IN	0
people	people	NNS	0
on	on	IN	0
any	any	DT	0
type	type	NN	0
of	of	IN	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
in	in	IN	0
1995	1995	CD	0
was	was	VBD	0
approximately	approximately	RB	0
6	6	CD	0
to	to	TO	0
7	7	CD	0
%	%	NN	0
of	of	IN	0
those	those	DT	0
with	with	IN	0
hypertension	hypertension	NN	0
[	[	-LRB-	0
5	5	LS	0
]	]	-RRB-	0
.	.	.	0
About	About	IN	0
80	80	CD	0
%	%	NN	0
of	of	IN	0
surveyed	surveyed	JJ	0
physicians	physicians	NNS	0
would	would	MD	0
choose	choose	VB	0
these	these	DT	0
drugs	drugs	NNS	0
as	as	IN	0
a	a	DT	0
first-line	first-line	JJ	B-NP
blood	blood	NN	I-NP
pressure	pressure	NN	I-NP
agent	agent	NN	I-NP
for	for	IN	0
patients	patients	NNS	0
with	with	IN	0
hypertension	hypertension	NN	0
and	and	CC	0
symptom	symptom	NN	B-NP
of	of	IN	0
BPH	BPH	NNP	B-NP
[	[	-LRB-	0
6	6	CD	0
]	]	-RRB-	0
.	.	.	0
Weight	Weight	NN	0
and	and	CC	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	NNP	I-NP
antagonist	antagonist	NN	I-NP
fluid	fluid	JJ	I-NP
status	status	NN	I-NP
were	were	VBD	0
consistently	consistently	RB	0
associated	associated	VBN	0
with	with	IN	0
fluid	fluid	JJ	B-NP
retention	retention	NN	I-NP
.	.	.	0
A	A	DT	0
1984	1984	CD	0
study	study	NN	0
of	of	IN	0
prazosin	prazosin	NN	B-NP
reported	reported	VBD	0
by	by	IN	0
Bauer	Bauer	NNP	0
revealed	revealed	VBD	B-NP
increase	increase	NN	I-NP
in	in	IN	0
plasma	plasma	JJ	B-NP
volume	volume	NN	I-NP
,	,	,	0
interstitial	interstitial	JJ	B-NP
fluid	fluid	JJ	I-NP
volume	volume	NN	I-NP
,	,	,	0
and	and	CC	0
extracellular	extracellular	JJ	B-NP
fluid	fluid	JJ	I-NP
volume	volume	NN	I-NP
following	following	VBG	0
both	both	DT	0
short-term	short-term	JJ	0
and	and	CC	0
long-term	long-term	JJ	0
therapy	therapy	NN	0
[	[	-LRB-	0
7	7	CD	0
]	]	-RRB-	0
.	.	.	0
In	In	IN	0
this	this	DT	0
study	study	NN	0
of	of	IN	0
14	14	CD	0
hypertensive	hypertensive	CD	B-NP
man	man	NN	I-NP
,	,	,	0
there	there	EX	0
was	was	VBD	0
a	a	DT	0
significant	significant	JJ	0
1.4	1.4	CD	0
L	L	NNP	0
average	average	JJ	0
increase	increase	NN	0
in	in	IN	0
ECFV	ECFV	NNP	B-NP
,	,	,	0
with	with	IN	0
a	a	DT	0
200	200	CD	0
mL	mL	JJ	B-NP
average	average	JJ	I-NP
increase	increase	NN	I-NP
in	in	IN	0
plasma	plasma	JJ	B-NP
volume	volume	NN	I-NP
(	(	-LRB-	0
measured	measured	VBN	0
with	with	IN	0
radioisotopic	radioisotopic	JJ	B-NP
assay	assay	NN	I-NP
)	)	-RRB-	0
that	that	WDT	0
occurred	occurred	VBD	0
within	within	IN	0
3-6	3-6	CD	0
weeks	weeks	NNS	0
of	of	IN	0
initiation	initiation	NN	0
,	,	,	0
lasted	lasted	VBD	0
during	during	IN	0
5	5	CD	0
to	to	TO	0
6	6	CD	0
months	months	NNS	0
of	of	IN	0
chronic	chronic	JJ	B-NP
therapy	therapy	NN	I-NP
,	,	,	0
and	and	CC	0
was	was	VBD	0
still	still	RB	0
present	present	VB	0
during	during	IN	0
a	a	DT	0
two-week	two-week	JJ	B-NP
washout	washout	JJ	I-NP
period	period	NN	I-NP
.	.	.	0
There	There	EX	0
was	was	VBD	0
no	no	DT	0
weight	weight	NN	B-NP
change	change	NN	I-NP
in	in	IN	0
that	that	DT	0
study	study	NN	0
,	,	,	0
but	but	CC	0
two	two	CD	0
other	other	JJ	0
studies	studies	NNS	0
demonstrated	demonstrated	VBD	0
both	both	PDT	0
an	an	DT	0
increase	increase	NN	0
in	in	IN	0
weight	weight	NN	0
as	as	IN	0
well	well	RB	0
as	as	IN	0
laboratory	laboratory	NN	B-NP
change	change	NN	I-NP
consistent	consistent	JJ	0
with	with	IN	0
prazosin	prazosin	NNS	B-NP
volume	volume	NN	I-NP
expansion	expansion	NN	I-NP
[	[	-LRB-	0
8	8	CD	0
9	9	CD	0
]	]	-RRB-	0
.	.	.	0
Bauer	Bauer	NNP	0
and	and	CC	0
his	his	PRP$	0
colleagues	colleagues	NNS	0
suggested	suggested	VBD	0
that	that	IN	0
a	a	DT	0
net	net	JJ	0
increase	increase	NN	0
in	in	IN	0
total	total	JJ	B-NP
body	body	NN	I-NP
sodium	sodium	NN	I-NP
from	from	IN	0
an	an	DT	0
acute	acute	JJ	0
prazosin	prazosin	NN	B-NP
renal	renal	JJ	I-NP
effect	effect	NN	I-NP
was	was	VBD	0
offset	offset	VBN	0
by	by	IN	0
a	a	DT	0
decrease	decrease	NN	0
in	in	IN	0
actual	actual	JJ	0
body	body	NN	0
weight	weight	NN	0
.	.	.	0
They	They	PRP	0
also	also	RB	0
demonstrated	demonstrated	VBN	0
that	that	IN	0
the	the	DT	0
sodium	sodium	NN	B-NP
fractional	fractional	JJ	I-NP
excretion	excretion	NN	I-NP
was	was	VBD	0
unchanged	unchanged	JJ	0
during	during	IN	0
treatment	treatment	NN	0
,	,	,	0
and	and	CC	0
further	further	RB	0
suggested	suggested	VBN	0
that	that	IN	0
the	the	DT	0
acute	acute	JJ	0
changes	changes	NNS	0
were	were	VBD	0
followed	followed	VBN	0
by	by	IN	0
chronic	chronic	JJ	B-NP
sodium	sodium	NN	I-NP
homeostasi	homeostasi	NN	I-NP
and	and	CC	0
maintenance	maintenance	NN	0
of	of	IN	0
the	the	DT	0
increased	increased	JJ	0
total	total	JJ	B-NP
body	body	NN	I-NP
sodium	sodium	NN	I-NP
.	.	.	0
The	The	DT	0
VA	VA	NNP	B-NP
Cooperative	Cooperative	NNP	I-NP
Study	Study	NNP	I-NP
on	on	IN	0
antihypertensive	antihypertensive	NN	B-NP
agent	agent	NN	I-NP
was	was	VBD	0
a	a	DT	0
double-blind	double-blind	JJ	B-NP
,	,	,	0
randomized	randomized	VBD	0
comparing	comparing	VBG	B-NP
atenolol	atenolol	NN	I-NP
controlled	controlled	VBN	I-NP
trial	trial	NN	I-NP
,	,	,	0
captopril	captopril	NN	B-NP
,	,	,	0
clonidine	clonidine	NN	B-NP
,	,	,	0
diltiazem	diltiazem	NN	B-NP
,	,	,	0
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP
,	,	,	0
prazosin	prazosin	NN	B-NP
,	,	,	0
and	and	CC	0
placebo	placebo	NN	0
for	for	IN	0
differences	differences	NNS	0
in	in	IN	0
antihypertensive	antihypertensive	JJ	B-NP
efficacy	efficacy	NN	I-NP
in	in	IN	0
1,105	1,105	CD	0
men	men	NNS	0
who	who	WP	0
had	had	VBD	0
mild	mild	JJ	0
diastolic	diastolic	JJ	B-NP
hypertension	hypertension	NN	I-NP
[	[	-LRB-	0
10	10	CD	0
]	]	-RRB-	0
.	.	.	0
A	A	DT	0
highly	highly	RB	0
significant	significant	JJ	0
weight	weight	NN	B-NP
gain	gain	NN	I-NP
of	of	IN	0
1	1	CD	0
kilogram	kilogram	NNS	0
was	was	VBD	0
observed	observed	VBN	0
at	at	IN	0
8	8	CD	0
weeks	weeks	NNS	0
with	with	IN	0
prazosin	prazosin	VBG	0
compared	compared	VBN	0
to	to	TO	0
baseline	baseline	VB	0
(	(	-LRB-	0
p	p	FW	0
<	<	SYM	0
.001	.001	FW	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
this	this	DT	0
gain	gain	NN	0
was	was	VBD	0
also	also	RB	0
statistically	statistically	RB	0
significant	significant	JJ	0
when	when	WRB	0
compared	compared	VBN	0
to	to	TO	0
the	the	DT	0
8-week	8-week	JJ	0
weight	weight	NN	B-NP
change	change	NN	I-NP
in	in	IN	0
all	all	DT	0
other	other	JJ	0
groups	groups	NNS	0
that	that	WDT	0
had	had	VBD	0
experienced	experienced	VBN	0
either	either	DT	0
weight	weight	NN	B-NP
loss	loss	NN	I-NP
or	or	CC	0
no	no	DT	0
mean	mean	JJ	0
weight	weight	NN	B-NP
change	change	NN	I-NP
(	(	-LRB-	0
p	p	CD	0
<	<	SYM	0
0.05	0.05	CD	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
prazosin	prazosin	JJ	B-NP
arm	arm	NN	I-NP
had	had	VBD	0
the	the	DT	0
highest	highest	JJS	0
rate	rate	NN	0
of	of	IN	0
adverse	adverse	JJ	0
effects	effects	NNS	0
,	,	,	0
leading	leading	VBG	0
to	to	TO	0
discontinuation	discontinuation	VB	0
of	of	IN	0
treatment	treatment	NN	0
.	.	.	0
The	The	DT	0
termination	termination	NN	B-NP
rate	rate	NN	I-NP
of	of	IN	0
13.8	13.8	CD	0
%	%	NN	0
was	was	VBD	0
higher	higher	JJR	0
than	than	IN	0
the	the	DT	0
termination	termination	NN	B-NP
rate	rate	NN	I-NP
from	from	IN	0
adverse	adverse	JJ	0
effects	effects	NNS	0
for	for	IN	0
clonidina	clonidina	NN	B-NP
(	(	-LRB-	0
10.1	10.1	CD	0
%	%	NN	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
significantly	significantly	RB	0
higher	higher	JJR	0
than	than	IN	0
the	the	DT	0
rates	rates	NNS	0
for	for	IN	0
captopril	captopril	NN	B-NP
(	(	-LRB-	0
4.8	4.8	CD	0
%	%	NN	0
)	)	-RRB-	0
,	,	,	0
atenolol	atenolol	NN	B-NP
(	(	-LRB-	0
2.2	2.2	CD	0
%	%	NN	0
)	)	-RRB-	0
,	,	,	0
or	or	CC	0
hydrochlorothiazida	hydrochlorothiazida	NN	B-NP
(	(	-LRB-	0
1.1	1.1	CD	0
%	%	NN	0
)	)	-RRB-	0
[	[	-LRB-	0
11	11	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
number	number	NN	0
of	of	IN	0
men	men	NNS	0
treated	treated	VBN	0
with	with	IN	0
prazosin	prazosin	JJ	B-NP
decreased	decreased	NN	I-NP
from	from	IN	0
62	62	CD	0
at	at	IN	0
the	the	DT	0
beginning	beginning	NN	0
of	of	IN	0
the	the	DT	0
trial	trial	NN	0
to	to	TO	0
28	28	CD	0
by	by	IN	0
the	the	DT	0
end	end	NN	0
.	.	.	0
The	The	DT	0
average	average	JJ	0
weight	weight	NN	B-NP
gain	gain	NN	I-NP
of	of	IN	0
0.5	0.5	CD	0
kilograms	kilograms	NNS	0
from	from	IN	0
baseline	baseline	NN	B-NP
was	was	VBD	0
no	no	DT	0
longer	longer	RBR	0
statistically	statistically	JJ	0
significant	significant	JJ	0
at	at	IN	0
one	one	CD	0
year	year	NN	0
of	of	IN	0
therapy	therapy	NN	0
when	when	WRB	0
compared	compared	VBN	0
to	to	TO	0
the	the	DT	0
original	original	JJ	B-NP
baseline	baseline	NN	I-NP
weight	weight	NN	I-NP
or	or	CC	0
the	the	DT	0
other	other	JJ	0
therapies	therapies	NNS	0
.	.	.	0
Safety	Safety	NNP	0
and	and	CC	0
tolerability	tolerability	JJ	B-NP
trial	trial	NN	I-NP
with	with	IN	0
terazosin	terazosin	NN	B-NP
have	have	VBP	0
shown	shown	VBN	0
similar	similar	JJ	0
results	results	NNS	0
(	(	-LRB-	0
Table	Table	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
Patients	Patients	NNS	0
treated	treated	VBN	0
with	with	IN	0
terazosin	terazosin	NN	B-NP
tended	tended	VBD	0
to	to	TO	0
gain	gain	VB	0
about	about	IN	0
1	1	CD	0
kilogram	kilogram	NN	0
from	from	IN	0
baseline	baseline	NN	B-NP
on	on	IN	0
active	active	JJ	0
therapy	therapy	NN	0
during	during	IN	0
these	these	DT	0
trials	trials	NNS	0
,	,	,	0
and	and	CC	0
those	those	DT	0
on	on	IN	0
placebo	placebo	JJ	0
therapy	therapy	NN	0
lost	lost	VBD	0
weight	weight	NN	0
.	.	.	0
Two	Two	CD	0
of	of	IN	0
the	the	DT	0
randomized	randomized	JJ	B-NP
trial	trial	NN	I-NP
included	included	VBD	0
a	a	DT	0
phase	phase	NN	0
for	for	IN	0
withdrawal	withdrawal	NN	B-NP
from	from	IN	0
active	active	JJ	0
therapy	therapy	NN	0
,	,	,	0
with	with	IN	0
weight	weight	NN	B-NP
information	information	NN	I-NP
reported	reported	VBD	0
by	by	IN	0
Ruoff	Ruoff	NNP	0
[	[	-LRB-	0
12	12	CD	0
]	]	-RRB-	0
.	.	.	0
Withdrawal	Withdrawal	NN	B-NP
from	from	IN	0
active	active	JJ	0
therapy	therapy	NN	0
was	was	VBD	0
associated	associated	VBN	0
with	with	IN	0
a	a	DT	0
loss	loss	NN	0
of	of	IN	0
1.3	1.3	CD	0
kilograms	kilograms	NNS	0
.	.	.	0
Doxazosin	Doxazosin	NNP	B-NP
has	has	VBZ	0
also	also	RB	0
been	been	VBN	0
associated	associated	VBN	0
with	with	IN	0
volume	volume	NN	B-NP
expansion	expansion	NN	I-NP
.	.	.	0
A	A	DT	0
physiology	physiology	JJ	B-NP
study	study	NN	I-NP
reported	reported	VBD	0
by	by	IN	0
Lund-Johansen	Lund-Johansen	NNP	B-NP
demonstrated	demonstrated	VBD	0
a	a	DT	0
plasma	plasma	JJ	B-NP
volume	volume	NN	I-NP
fluid	fluid	NN	I-NP
expansion	expansion	NN	I-NP
of	of	IN	0
about	about	IN	0
10	10	CD	0
%	%	NN	0
when	when	WRB	0
compared	compared	VBN	0
to	to	TO	0
baseline	baseline	VB	0
values	values	NNS	0
[	[	-LRB-	0
13	13	CD	0
]	]	-RRB-	0
.	.	.	0
Larger	Larger	JJR	0
randomized	randomized	NNS	0
controlled	controlled	VBN	B-NP
trial	trial	NN	I-NP
have	have	VBP	0
also	also	RB	0
consistently	consistently	RB	0
demonstrated	demonstrated	VBN	0
that	that	IN	0
patients	patients	NNS	0
treated	treated	VBN	0
with	with	IN	0
doxazosin	doxazosin	JJ	B-NP
gain	gain	NN	I-NP
weight	weight	NN	I-NP
,	,	,	0
as	as	IN	0
summarized	summarized	NN	0
in	in	IN	0
Table	Table	NNP	0
2	2	CD	0
.	.	.	0
While	While	IN	0
patients	patients	NNS	0
treated	treated	VBN	0
with	with	IN	0
doxazosin	doxazosin	NN	B-NP
tend	tend	VBP	0
to	to	TO	0
gain	gain	VB	0
weight	weight	NN	0
,	,	,	0
patients	patients	NNS	0
on	on	IN	0
placebo	placebo	JJ	0
therapy	therapy	NN	0
lost	lost	VBD	0
weight	weight	NN	0
.	.	.	0
The	The	DT	0
Treatment	Treatment	NNP	B-NP
of	of	IN	I-NP
Mild	Mild	NNP	I-NP
Hypertension	Hypertension	NNP	I-NP
Study	Study	NNP	I-NP
(	(	-LRB-	0
treatment	treatment	NN	B-NP
of	of	IN	I-NP
mild	mild	JJ	I-NP
hypertension	hypertension	NN	I-NP
study	study	NN	I-NP
)	)	-RRB-	0
trial	trial	NN	0
is	is	VBZ	0
a	a	DT	0
notable	notable	JJ	0
exception	exception	NN	0
for	for	IN	0
the	the	DT	0
trend	trend	NN	0
towards	towards	IN	0
weight	weight	NN	B-NP
gain	gain	NN	I-NP
[	[	-LRB-	0
14	14	CD	0
]	]	-RRB-	0
.	.	.	0
All	All	DT	0
five	five	CD	0
treatment	treatment	NN	B-NP
group	group	NN	I-NP
and	and	CC	0
the	the	DT	0
placebo	placebo	JJ	0
group	group	NN	0
received	received	VBD	0
intensive	intensive	JJ	B-NP
dietary	dietary	JJ	I-NP
counseling	counseling	NN	I-NP
aimed	aimed	VBN	0
at	at	IN	0
weight	weight	NN	B-NP
loss	loss	NN	I-NP
,	,	,	0
and	and	CC	0
all	all	DT	0
groups	groups	NNS	0
lost	lost	VBD	0
weight	weight	NN	0
without	without	IN	0
significant	significant	JJ	0
differences	differences	NNS	0
between	between	IN	0
trial	trial	NN	B-NP
arm	arm	NN	I-NP
.	.	.	0
Neurohormonal	Neurohormonal	NNP	B-NP
and	and	CC	0
physiologic	physiologic	NN	B-NP
study	study	NN	I-NP
cellular	cellular	JJ	I-NP
effect	effect	NN	I-NP
with	with	IN	0
small	small	JJ	0
numbers	numbers	NNS	0
of	of	IN	0
participant	participant	NN	B-NP
are	are	VBP	0
by	by	IN	0
nature	nature	NN	0
underpowered	underpowered	NN	0
to	to	TO	0
detect	detect	VB	0
meaningful	meaningful	JJ	0
population	population	NN	B-NP
difference	difference	NN	I-NP
,	,	,	0
but	but	CC	0
may	may	MD	0
provide	provide	VB	0
a	a	DT	0
starting	starting	VBG	B-NP
point	point	NN	I-NP
when	when	WRB	0
such	such	JJ	0
data	data	NNS	0
are	are	VBP	0
not	not	RB	0
available	available	JJ	0
.	.	.	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
were	were	VBD	0
associated	associated	VBN	0
with	with	IN	0
perturbation	perturbation	NN	B-NP
in	in	IN	0
neurohormonal	neurohormonal	JJ	B-NP
level	level	JJ	I-NP
in	in	IN	0
various	various	JJ	0
studies	studies	NNS	0
.	.	.	0
In	In	IN	0
particular	particular	JJ	0
,	,	,	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
are	are	VBP	0
associated	associated	VBN	0
with	with	IN	0
an	an	DT	0
increase	increase	NN	0
in	in	IN	0
plasma	plasma	JJ	B-NP
norepinephrine	norepinephrine	NN	I-NP
in	in	IN	0
diverse	diverse	JJ	B-NP
patient	patient	NN	I-NP
population	population	NN	I-NP
,	,	,	0
as	as	IN	0
summarized	summarized	NN	0
in	in	IN	0
Table	Table	NNP	0
3	3	CD	0
.	.	.	0
This	This	DT	0
table	table	NN	0
reflects	reflects	VBZ	0
increases	increases	NNS	0
in	in	IN	0
norepinephrine	norepinephrine	NN	B-NP
in	in	IN	0
normotensive	normotensive	JJ	B-NP
patient	patient	JJ	I-NP
,	,	,	0
hypertensive	hypertensive	JJ	B-NP
patient	patient	JJ	I-NP
,	,	,	0
and	and	CC	0
patients	patients	NNS	0
with	with	IN	0
chronic	chronic	JJ	B-NP
congestive	congestive	JJ	I-NP
heart	heart	NN	I-NP
failure	failure	NN	I-NP
from	from	IN	0
a	a	DT	0
variety	variety	NN	0
of	of	IN	0
these	these	DT	0
small	small	JJ	0
studies	studies	NNS	0
.	.	.	0
Several	Several	JJ	0
lines	lines	NNS	0
of	of	IN	0
evidence	evidence	NN	0
suggest	suggest	VBP	0
that	that	IN	0
elevated	elevated	JJ	0
catecholamine	catecholamine	JJ	B-NP
level	level	JJ	I-NP
are	are	VBP	0
cardiotoxic	cardiotoxic	NN	B-NP
[	[	-LRB-	0
15	15	CD	0
]	]	-RRB-	0
.	.	.	0
norepinephrine	norepinephrine	JJ	B-NP
level	level	JJ	I-NP
elevated	elevated	VBN	I-NP
plasma	plasma	JJ	I-NP
are	are	VBP	0
hypothesized	hypothesized	VBN	0
to	to	TO	0
cause	cause	VB	0
direct	direct	JJ	0
myocardial	myocardial	JJ	B-NP
damage	damage	NN	I-NP
through	through	IN	0
many	many	JJ	0
mechanisms	mechanisms	NNS	0
,	,	,	0
which	which	WDT	0
may	may	MD	0
be	be	VB	0
amplified	amplified	VBN	0
by	by	IN	0
concomitant	concomitant	CD	B-NP
alpha-1	alpha-1	CD	I-NP
blockade	blockade	NN	I-NP
.	.	.	0
In	In	IN	0
rats	rats	NNS	0
,	,	,	0
norepinephrine	norepinephrine	NN	B-NP
stimulates	stimulates	FW	0
apoptosi	apoptosi	NN	B-NP
,	,	,	0
which	which	WDT	0
is	is	VBZ	0
mediated	mediated	VBN	0
through	through	IN	0
beta	beta	JJ	B-NP
receptor	receptor	NN	I-NP
[	[	-LRB-	0
16	16	CD	0
]	]	-RRB-	0
.	.	.	0
In	In	IN	0
addition	addition	NN	B-NP
,	,	,	0
cardiac	cardiac	JJ	B-NP
receptor	receptor	NN	I-NP
alpha-1	alpha-1	CD	I-NP
inhibit	inhibit	VBP	0
this	this	DT	0
response	response	NN	0
in	in	IN	0
rat	rat	JJ	B-NP
myocyte	myocyte	NN	I-NP
[	[	-LRB-	0
17	17	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
increased	increased	JJ	0
norepinephrine	norepinephrine	NNS	B-NP
concentration	concentration	NN	I-NP
leading	leading	VBG	0
to	to	TO	0
cardiac	cardiac	VB	B-NP
beta	beta	JJ	I-NP
receptor	receptor	NN	I-NP
stimulation	stimulation	VBZ	I-NP
combined	combined	VBN	0
with	with	IN	0
alpha-1	alpha-1	CD	B-NP
receptor	receptor	NN	I-NP
inhibition	inhibition	NN	I-NP
may	may	MD	0
lead	lead	VB	0
to	to	TO	0
increased	increased	JJ	0
apoptosi	apoptosi	NN	B-NP
in	in	IN	0
myocyte	myocyte	NN	B-NP
.	.	.	0
Other	Other	JJ	0
hormones	hormones	NNS	0
that	that	WDT	0
are	are	VBP	0
associated	associated	VBN	0
with	with	IN	0
cardiovascular	cardiovascular	JJ	B-NP
disease	disease	NN	I-NP
are	are	VBP	0
affected	affected	VBN	0
by	by	IN	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
.	.	.	0
Endothelin-1	Endothelin-1	NNP	B-NP
is	is	VBZ	0
a	a	DT	0
vascular	vascular	JJ	B-NP
hormone	hormone	NN	I-NP
,	,	,	0
which	which	WDT	0
may	may	MD	0
play	play	VB	0
a	a	DT	0
role	role	NN	0
in	in	IN	0
the	the	DT	0
generation	generation	NN	0
and	and	CC	0
maintenance	maintenance	NN	0
of	of	IN	0
heart	heart	NN	B-NP
failure	failure	NN	I-NP
[	[	-LRB-	0
18	18	CD	0
]	]	-RRB-	0
.	.	.	0
In	In	IN	0
hypertensive	hypertensive	JJ	B-NP
patient	patient	JJ	I-NP
,	,	,	0
doxazosin	doxazosin	NN	B-NP
lowers	lowers	VBZ	0
von	von	NNP	B-NP
Willebrand	Willebrand	NNP	I-NP
factor	factor	NN	I-NP
commensurate	commensurate	NN	0
with	with	IN	0
blood	blood	NN	0
pressure	pressure	NN	0
,	,	,	0
but	but	CC	0
it	it	PRP	0
does	does	VBZ	0
not	not	RB	0
lower	lower	RBR	0
high	high	JJ	0
levels	levels	NNS	0
of	of	IN	0
endothelin-1	endothelin-1	CD	B-NP
while	while	IN	0
atenolol	atenolol	NN	B-NP
does	does	VBZ	0
[	[	-LRB-	0
19	19	CD	0
]	]	-RRB-	0
.	.	.	0
Other	Other	JJ	0
mechanisms	mechanisms	NNS	0
for	for	IN	0
cellular	cellular	JJ	B-NP
injury	injury	NN	I-NP
have	have	VBP	0
been	been	VBN	0
suggested	suggested	VBN	0
.	.	.	0
Hooper	Hooper	RB	0
proposed	proposed	VBN	0
that	that	IN	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
alter	alter	VBP	0
cellular	cellular	JJ	B-NP
repair	repair	NN	I-NP
mechanism	mechanism	NN	I-NP
,	,	,	0
possibly	possibly	RB	0
causing	causing	VBG	0
cardiac	cardiac	JJ	B-NP
damage	damage	NN	I-NP
.	.	.	0
He	He	PRP	0
noted	noted	VBD	0
that	that	DT	0
heat	heat	NN	B-NP
shock	shock	NN	I-NP
protein	protein	NN	I-NP
expression	expression	NN	I-NP
prazosin	prazosin	JJ	I-NP
block	block	NN	I-NP
in	in	IN	0
myocardium	myocardium	NN	B-NP
,	,	,	0
and	and	CC	0
it	it	PRP	0
has	has	VBZ	0
been	been	VBN	0
hypothesized	hypothesized	VBN	0
that	that	IN	0
this	this	DT	0
may	may	MD	0
leave	leave	VB	0
myocardium	myocardium	VBN	0
more	more	RBR	0
vulnerable	vulnerable	JJ	0
to	to	TO	0
injury	injury	VB	B-NP
[	[	-LRB-	0
20	20	CD	0
]	]	-RRB-	0
.	.	.	0
Epidemiological	Epidemiological	NNP	B-NP
and	and	CC	0
Clinical	Clinical	NNP	B-NP
Trial	Trial	NNP	I-NP
Data	Data	NNP	I-NP
Between	Between	IN	0
1966	1966	CD	0
and	and	CC	0
2001	2001	CD	0
,	,	,	0
there	there	EX	0
were	were	VBD	0
188	188	CD	0
published	published	VBN	0
cardiovascular	cardiovascular	JJ	0
randomized	randomized	NNS	0
controlled	controlled	VBN	B-NP
trial	trial	NN	I-NP
related	related	VBN	0
to	to	TO	0
the	the	DT	0
treatment	treatment	NN	0
of	of	IN	0
hypertension	hypertension	NN	0
with	with	IN	0
the	the	DT	0
use	use	NN	0
of	of	IN	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
.	.	.	0
Among	Among	IN	0
these	these	DT	0
,	,	,	0
only	only	RB	0
ALLHAT	ALLHAT	NNP	B-NP
specifically	specifically	RB	0
assessed	assessed	VBN	B-NP
difference	difference	NN	I-NP
in	in	IN	0
cardiovascular	cardiovascular	JJ	B-NP
endpoint	endpoint	NN	I-NP
resulting	resulting	VBG	0
from	from	IN	0
control	control	NN	0
of	of	IN	0
hypertension	hypertension	NN	0
with	with	IN	0
a	a	DT	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
.	.	.	0
Most	Most	JJS	0
of	of	IN	0
these	these	DT	0
trials	trials	NNS	0
focused	focused	VBN	0
on	on	IN	0
surrogate	surrogate	JJ	0
endpoints	endpoints	JJ	0
such	such	JJ	0
as	as	IN	0
equivalence	equivalence	NN	0
of	of	IN	0
blood-pressure	blood-pressure	JJ	B-NP
reduction	reduction	NN	I-NP
and	and	CC	0
effects	effects	NNS	0
on	on	IN	0
cholesterol	cholesterol	NN	B-NP
.	.	.	0
Other	Other	JJ	0
studies	studies	NNS	0
focused	focused	VBN	0
on	on	IN	0
tolerability	tolerability	NN	B-NP
and	and	CC	0
pharmacology	pharmacology	NN	0
.	.	.	0
There	There	EX	0
are	are	VBP	0
no	no	DT	0
case	case	NN	B-NP
control	control	NN	I-NP
,	,	,	0
cohort	cohort	NN	B-NP
,	,	,	0
or	or	CC	0
other	other	JJ	0
studies	studies	NNS	0
that	that	WDT	0
analyzed	analyzed	VBD	0
the	the	DT	0
impact	impact	NN	0
of	of	IN	0
these	these	DT	0
agents	agents	NNS	0
on	on	IN	0
cardiovascular	cardiovascular	JJ	B-NP
endpoint	endpoint	NN	I-NP
.	.	.	0
Using	Using	VBG	0
data	data	NNS	0
from	from	IN	0
other	other	JJ	0
trials	trials	NNS	0
may	may	MD	0
offer	offer	VB	0
a	a	DT	0
partial	partial	JJ	0
framework	framework	NN	0
for	for	IN	0
the	the	DT	0
interpretation	interpretation	NN	B-NP
of	of	IN	0
newer	newer	JJR	0
findings	findings	NNS	0
.	.	.	0
ALLHAT	ALLHAT	NNP	B-NP
demonstrated	demonstrated	VBD	0
a	a	DT	0
highly	highly	RB	0
statistically	statistically	RB	0
significant	significant	JJ	0
,	,	,	0
near	near	IN	0
doubling	doubling	VBG	0
in	in	IN	0
the	the	DT	0
incidence	incidence	NN	0
of	of	IN	0
heart	heart	NN	B-NP
failure	failure	NN	I-NP
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
arm	arm	NN	I-NP
compared	compared	VBN	0
to	to	TO	0
heart	heart	NN	B-NP
failure	failure	NN	I-NP
occurrence	occurrence	NN	I-NP
in	in	IN	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
arm	arm	NN	I-NP
.	.	.	0
Although	Although	IN	0
there	there	EX	0
was	was	VBD	0
no	no	DT	0
difference	difference	NN	0
in	in	IN	0
the	the	DT	0
coronary	coronary	JJ	B-NP
heart	heart	NN	I-NP
disease	disease	NN	I-NP
primary	primary	JJ	I-NP
outcome	outcome	NN	I-NP
or	or	CC	0
the	the	DT	0
total	total	JJ	B-NP
mortality	mortality	NN	I-NP
secondary	secondary	JJ	I-NP
outcome	outcome	NN	I-NP
,	,	,	0
there	there	EX	0
were	were	VBD	0
small	small	JJ	0
but	but	CC	0
statistically	statistically	RB	0
significant	significant	JJ	0
increases	increases	NNS	0
in	in	IN	0
the	the	DT	0
secondary	secondary	JJ	B-NP
outcome	outcome	NN	I-NP
of	of	IN	0
angina	angina	NNS	0
(	(	-LRB-	0
relative	relative	JJ	B-NP
risk	risk	NN	I-NP
1.16	1.16	CD	0
,	,	,	0
95	95	CD	0
%	%	NN	0
CI	CI	NNP	0
1.05-1.27	1.05-1.27	NNP	0
)	)	-RRB-	0
and	and	CC	0
stroke	stroke	NN	0
(	(	-LRB-	0
relative	relative	JJ	B-NP
risk	risk	NN	I-NP
1.19	1.19	CD	0
,	,	,	0
95	95	CD	0
%	%	NN	0
CI	CI	NNP	0
1.01-1.40	1.01-1.40	NNP	0
)	)	-RRB-	0
.	.	.	0
Since	Since	IN	0
ALLHAT	ALLHAT	NNP	B-NP
is	is	VBZ	0
a	a	DT	0
comparative	comparative	JJ	B-NP
trial	trial	NN	I-NP
,	,	,	0
we	we	PRP	0
know	know	VBP	0
that	that	DT	0
doxazosin	doxazosin	NN	B-NP
is	is	VBZ	0
associated	associated	VBN	0
with	with	IN	0
more	more	RBR	0
adverse	adverse	JJ	0
cardiovascular	cardiovascular	JJ	B-NP
outcome	outcome	NN	I-NP
than	than	IN	0
low-dose	low-dose	JJ	B-NP
chlorthalidone	chlorthalidone	NN	I-NP
,	,	,	0
but	but	CC	0
we	we	PRP	0
do	do	VBP	0
not	not	RB	0
know	know	VB	0
how	how	WRB	0
doxazosin	doxazosin	NN	B-NP
might	might	MD	0
compare	compare	VB	0
with	with	IN	0
placebo	placebo	NN	0
.	.	.	0
The	The	DT	0
SHEP	SHEP	NNP	B-NP
trial	trial	NN	I-NP
,	,	,	0
however	however	RB	0
,	,	,	0
does	does	VBZ	0
provide	provide	VB	0
a	a	DT	0
comparison	comparison	NN	0
between	between	IN	0
chlorthalidone	chlorthalidone	NN	B-NP
and	and	CC	0
placebo	placebo	JJ	0
therapy	therapy	NN	0
for	for	IN	0
a	a	DT	0
heart	heart	NN	B-NP
failure	failure	NN	I-NP
reference	reference	NN	I-NP
point	point	NN	I-NP
,	,	,	0
although	although	IN	0
the	the	DT	0
study	study	NN	B-NP
population	population	NN	I-NP
have	have	VBP	0
different	different	JJ	0
demographic	demographic	NN	B-NP
and	and	CC	0
blood	blood	NN	0
pressure	pressure	NN	0
distributions	distributions	NNS	0
[	[	-LRB-	0
21	21	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
SHEP	SHEP	NNP	B-NP
trial	trial	NN	I-NP
included	included	VBD	0
4,736	4,736	CD	0
people	people	NNS	0
aged	aged	VBN	0
60	60	CD	0
and	and	CC	0
older	older	NNS	0
who	who	WP	0
had	had	VBD	0
a	a	DT	0
systolic	systolic	JJ	B-NP
blood	blood	NN	I-NP
pressure	pressure	NN	I-NP
of	of	IN	0
160	160	CD	0
to	to	TO	0
219	219	CD	0
mmHg	mmHg	JJ	0
and	and	CC	0
a	a	DT	0
diastolic	diastolic	JJ	B-NP
blood	blood	NN	I-NP
pressure	pressure	NN	I-NP
of	of	IN	0
less	less	JJR	0
than	than	IN	0
90	90	CD	0
mmHg	mmHg	NN	B-NP
.	.	.	0
subject	subject	JJ	B-NP
were	were	VBD	0
randomized	randomized	VBN	0
to	to	TO	0
low-dose	low-dose	JJ	B-NP
diuretic	diuretic	NN	I-NP
or	or	CC	0
placebo	placebo	NN	0
,	,	,	0
and	and	CC	0
were	were	VBD	0
followed	followed	VBN	0
for	for	IN	0
an	an	DT	0
average	average	NN	0
of	of	IN	0
4.5	4.5	CD	0
years	years	NNS	0
for	for	IN	0
major	major	JJ	0
CV	CV	NN	0
events	events	NNS	0
.	.	.	0
Comparisons	Comparisons	NNS	0
between	between	IN	0
those	those	DT	0
randomized	randomized	NN	0
to	to	TO	0
active	active	JJ	0
therapy	therapy	NN	0
and	and	CC	0
those	those	DT	0
on	on	IN	0
placebo	placebo	NN	0
demonstrated	demonstrated	VBD	0
nearly	nearly	RB	0
a	a	DT	0
50	50	CD	0
%	%	NN	0
reduction	reduction	NN	0
in	in	IN	0
fatal	fatal	JJ	0
and	and	CC	0
nonfatal	nonfatal	JJ	B-NP
heart	heart	NN	I-NP
failure	failure	NN	I-NP
event	event	NN	I-NP
(	(	-LRB-	0
relative	relative	JJ	B-NP
risk	risk	NN	I-NP
0.51	0.51	NNP	0
,	,	,	0
95	95	CD	0
%	%	NN	0
CI	CI	NNP	0
0.37-0.71	0.37-0.71	NNP	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
rates	rates	NNS	0
of	of	IN	0
CHF	CHF	NNP	B-NP
in	in	IN	0
shep	shep	NN	B-NP
participant	participant	NN	I-NP
treated	treated	VBN	0
with	with	IN	0
diuretic	diuretic	NN	B-NP
and	and	CC	0
placebo	placebo	NN	0
were	were	VBD	0
5	5	CD	0
and	and	CC	0
10	10	CD	0
per	per	IN	0
1,000	1,000	CD	0
person-year	person-year	NN	B-NP
,	,	,	0
respectively	respectively	RB	0
.	.	.	0
In	In	IN	0
comparison	comparison	NN	0
,	,	,	0
the	the	DT	0
rates	rates	NNS	0
of	of	IN	0
CHF	CHF	NNP	B-NP
in	in	IN	0
allhat	allhat	NN	B-NP
participant	participant	NN	I-NP
treated	treated	VBN	0
with	with	IN	0
diuretic	diuretic	NN	B-NP
and	and	CC	0
doxazosin	doxazosin	NN	B-NP
were	were	VBD	0
10	10	CD	0
and	and	CC	0
20	20	CD	0
per	per	IN	0
1,000	1,000	CD	0
person-year	person-year	NN	B-NP
,	,	,	0
respectively	respectively	RB	0
.	.	.	0
If	If	IN	0
low-dose	low-dose	JJ	B-NP
chlorthalidone	chlorthalidone	NN	I-NP
has	has	VBZ	0
a	a	DT	0
similar	similar	JJ	0
risk	risk	NN	B-NP
reduction	reduction	NN	I-NP
in	in	IN	0
the	the	DT	0
ALLHAT	ALLHAT	NNP	B-NP
population	population	NN	I-NP
,	,	,	0
and	and	CC	0
halves	halves	VBZ	0
the	the	DT	0
incidence	incidence	NN	0
of	of	IN	0
clinical	clinical	JJ	B-NP
heart	heart	NN	I-NP
failure	failure	NN	I-NP
event	event	NN	I-NP
compared	compared	VBN	0
to	to	TO	0
no	no	DT	0
therapy	therapy	NN	0
,	,	,	0
the	the	DT	0
effect	effect	NN	0
of	of	IN	0
doxazosin	doxazosin	NN	B-NP
would	would	MD	0
be	be	VB	0
comparable	comparable	JJ	0
to	to	TO	0
that	that	DT	0
of	of	IN	0
the	the	DT	0
placebo	placebo	JJ	0
arm	arm	NN	0
in	in	IN	0
the	the	DT	0
SHEP	SHEP	NNP	B-NP
trial	trial	NN	I-NP
.	.	.	0
Conclusions	Conclusions	NNS	0
The	The	DT	0
report	report	NN	0
of	of	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
arm	arm	NN	I-NP
termination	termination	NN	I-NP
in	in	IN	0
ALLHAT	ALLHAT	NNP	B-NP
was	was	VBD	0
published	published	VBN	0
in	in	IN	0
April	April	NNP	0
,	,	,	0
2000	2000	CD	0
.	.	.	0
At	At	IN	0
that	that	DT	0
time	time	NN	0
,	,	,	0
the	the	DT	0
results	results	NNS	0
of	of	IN	0
the	the	DT	0
ALLHAT	ALLHAT	NNP	B-NP
trial	trial	NN	I-NP
were	were	VBD	0
unexpected	unexpected	JJ	0
,	,	,	0
given	given	VBN	0
the	the	DT	0
potential	potential	JJ	B-NP
association	association	NN	I-NP
between	between	IN	0
high	high	JJ	0
dose	dose	NN	B-NP
diuretic	diuretic	NN	I-NP
and	and	CC	0
the	the	DT	0
risk	risk	NN	0
of	of	IN	0
sudden	sudden	JJ	0
death	death	NN	0
[	[	-LRB-	0
22	22	CD	0
]	]	-RRB-	0
,	,	,	0
and	and	CC	0
the	the	DT	0
favorable	favorable	JJ	0
effect	effect	NN	0
of	of	IN	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
on	on	IN	0
lipid	lipid	JJ	B-NP
profile	profile	NN	I-NP
[	[	-LRB-	0
14	14	CD	0
]	]	-RRB-	0
.	.	.	0
Comparing	Comparing	VBG	B-NP
data	data	NN	I-NP
from	from	IN	0
other	other	JJ	0
studies	studies	NNS	0
suggests	suggests	VBZ	0
the	the	DT	0
possibility	possibility	NN	0
that	that	IN	0
the	the	DT	0
beneficial	beneficial	JJ	0
effects	effects	NNS	0
of	of	IN	0
lowering	lowering	VBG	B-NP
blood	blood	NN	I-NP
pressure	pressure	NN	I-NP
peripheral	peripheral	JJ	I-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
may	may	MD	0
be	be	VB	0
nullified	nullified	VBN	0
by	by	IN	0
a	a	DT	0
negative	negative	JJ	B-NP
effect	effect	NN	I-NP
,	,	,	0
or	or	CC	0
that	that	DT	0
other	other	JJ	0
antihypertensive	antihypertensive	NN	B-NP
have	have	VBP	0
positive	positive	JJ	B-NP
action	action	NN	I-NP
beyond	beyond	IN	0
their	their	PRP$	0
antihypertensive	antihypertensive	JJ	B-NP
effect	effect	NN	I-NP
.	.	.	0
Those	Those	DT	0
treated	treated	VBN	0
with	with	IN	0
doxazosin	doxazosin	NN	B-NP
in	in	IN	0
ALLHAT	ALLHAT	NNP	B-NP
had	had	VBD	0
a	a	DT	0
mean	mean	JJ	0
blood	blood	NN	0
pressure	pressure	NN	0
that	that	WDT	0
was	was	VBD	0
2	2	CD	0
to	to	TO	0
3	3	CD	0
mmHg	mmHg	JJ	B-NP
higher	higher	JJR	I-NP
than	than	IN	0
the	the	DT	0
mean	mean	JJ	0
blood	blood	NN	0
pressure	pressure	NN	0
of	of	IN	0
those	those	DT	0
treated	treated	VBN	0
with	with	IN	0
chlorthalidone	chlorthalidone	NN	B-NP
.	.	.	0
Based	Based	VBN	0
on	on	IN	0
framingham	framingham	NN	B-NP
heart	heart	NN	I-NP
study	study	NN	I-NP
logistic	logistic	NN	I-NP
regression	regression	NN	I-NP
coefficient	coefficient	NN	I-NP
,	,	,	0
this	this	DT	0
2	2	CD	0
to	to	TO	0
3	3	CD	0
mmHg	mmHg	JJ	B-NP
difference	difference	NN	I-NP
in	in	IN	0
systolic	systolic	JJ	B-NP
blood	blood	NN	I-NP
pressure	pressure	NN	I-NP
is	is	VBZ	0
associated	associated	VBN	0
with	with	IN	0
an	an	DT	0
increased	increased	JJ	0
relative	relative	JJ	B-NP
risk	risk	NN	I-NP
of	of	IN	0
only	only	RB	0
1.06	1.06	CD	0
to	to	TO	0
1.09	1.09	CD	0
[	[	-LRB-	0
23	23	CD	0
]	]	-RRB-	0
.	.	.	0
From	From	IN	0
available	available	JJ	0
data	data	NNS	0
,	,	,	0
it	it	PRP	0
appears	appears	VBZ	0
that	that	IN	0
this	this	DT	0
average	average	JJ	0
difference	difference	NN	0
in	in	IN	0
systolic	systolic	JJ	B-NP
blood	blood	NN	I-NP
pressure	pressure	NN	I-NP
is	is	VBZ	0
not	not	RB	0
large	large	JJ	0
enough	enough	JJ	0
to	to	TO	0
double	double	VB	0
the	the	DT	0
average	average	JJ	0
incidence	incidence	NN	0
of	of	IN	0
CHF	CHF	NNP	B-NP
.	.	.	0
The	The	DT	0
literature	literature	NN	0
suggests	suggests	VBZ	0
several	several	JJ	0
mechanisms	mechanisms	NNS	0
by	by	IN	0
which	which	WDT	0
peripheral	peripheral	VBD	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
in	in	IN	0
general	general	JJ	0
and	and	CC	0
doxazosin	doxazosin	NN	B-NP
in	in	IN	0
particular	particular	JJ	0
might	might	MD	0
prove	prove	VB	0
inferior	inferior	JJ	0
to	to	TO	0
other	other	JJ	0
types	types	NNS	0
of	of	IN	0
antihypertensive	antihypertensive	JJ	B-NP
therapy	therapy	NN	I-NP
.	.	.	0
They	They	PRP	0
are	are	VBP	0
associated	associated	VBN	0
with	with	IN	0
a	a	DT	0
mild	mild	JJ	0
volume	volume	NN	B-NP
expansion	expansion	NN	I-NP
,	,	,	0
which	which	WDT	0
may	may	MD	0
precipitate	precipitate	VB	0
the	the	DT	0
heart	heart	NN	B-NP
failure	failure	NN	I-NP
clinical	clinical	JJ	I-NP
presentation	presentation	NN	I-NP
in	in	IN	0
those	those	DT	0
with	with	IN	0
subclinical	subclinical	JJ	B-NP
disease	disease	NN	I-NP
.	.	.	0
If	If	IN	0
this	this	DT	0
is	is	VBZ	0
the	the	DT	0
mechanism	mechanism	NN	0
responsible	responsible	JJ	0
for	for	IN	0
increasing	increasing	VBG	0
the	the	DT	0
incidence	incidence	NN	0
of	of	IN	0
CHF	CHF	NNP	B-NP
in	in	IN	0
the	the	DT	0
ALLHAT	ALLHAT	NNP	B-NP
trial	trial	NN	I-NP
,	,	,	0
it	it	PRP	0
would	would	MD	0
be	be	VB	0
consistent	consistent	JJ	0
with	with	IN	0
the	the	DT	0
early	early	JJ	0
divergence	divergence	NN	0
of	of	IN	0
the	the	DT	0
kaplan-meier	kaplan-meier	NN	B-NP
curve	curve	NN	I-NP
in	in	IN	0
that	that	DT	0
study	study	NN	0
.	.	.	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	NNP	I-NP
antagonist	antagonist	NN	I-NP
also	also	RB	0
cause	cause	VB	0
neurohormonal	neurohormonal	JJ	B-NP
change	change	NN	I-NP
during	during	IN	0
chronic	chronic	JJ	B-NP
therapy	therapy	NN	I-NP
.	.	.	0
The	The	DT	0
long-term	long-term	JJ	0
ramification	ramification	NN	B-NP
of	of	IN	0
these	these	DT	0
changes	changes	NNS	0
for	for	IN	0
patients	patients	NNS	0
being	being	VBG	0
treated	treated	VBN	0
for	for	IN	0
hypertension	hypertension	NNS	0
are	are	VBP	0
not	not	RB	0
known	known	VBN	0
.	.	.	0
These	These	DT	0
drugs	drugs	NNS	0
appear	appear	VBP	0
to	to	TO	0
cause	cause	VB	0
increases	increases	NNS	0
in	in	IN	0
norepinephrine	norepinephrine	NN	B-NP
,	,	,	0
and	and	CC	0
this	this	DT	0
increase	increase	NN	0
may	may	MD	0
nullify	nullify	VB	0
the	the	DT	0
beneficial	beneficial	JJ	0
effect	effect	NN	0
of	of	IN	0
lowered	lowered	JJ	0
blood	blood	NN	0
pressure	pressure	NN	0
on	on	IN	0
the	the	DT	0
occurrence	occurrence	NN	0
of	of	IN	0
CHF	CHF	NNP	B-NP
.	.	.	0
Not	Not	RB	0
only	only	RB	0
are	are	VBP	0
increased	increased	VBN	B-NP
plasma	plasma	NN	I-NP
catecholamines	catecholamines	VBP	0
a	a	DT	0
central	central	JJ	0
feature	feature	NN	0
in	in	IN	0
heart	heart	NN	B-NP
failure	failure	NN	I-NP
,	,	,	0
they	they	PRP	0
are	are	VBP	0
now	now	RB	0
a	a	DT	0
recommended	recommended	JJ	0
target	target	NN	0
for	for	IN	0
effective	effective	JJ	0
life-prolonging	life-prolonging	JJ	B-NP
therapy	therapy	NN	I-NP
[	[	-LRB-	0
24	24	CD	0
25	25	CD	0
26	26	CD	0
]	]	-RRB-	0
.	.	.	0
Given	Given	VBN	0
that	that	IN	0
doxazosin	doxazosin	NN	B-NP
is	is	VBZ	0
not	not	RB	0
as	as	IN	0
effective	effective	JJ	0
as	as	IN	0
chlorthalidone	chlorthalidone	NN	B-NP
in	in	IN	0
reducing	reducing	VBG	0
the	the	DT	0
cardiovascular	cardiovascular	JJ	B-NP
complication	complication	NN	I-NP
of	of	IN	0
hypertension	hypertension	NN	0
,	,	,	0
several	several	JJ	0
questions	questions	NNS	0
remain	remain	VBP	0
.	.	.	0
There	There	EX	0
is	is	VBZ	0
still	still	RB	0
a	a	DT	0
paucity	paucity	NN	0
of	of	IN	0
information	information	NN	0
regarding	regarding	VBG	0
the	the	DT	0
absolute	absolute	JJ	0
clinical	clinical	JJ	B-NP
heart	heart	NN	I-NP
failure	failure	NN	I-NP
risk	risk	NN	I-NP
reduction	reduction	NN	I-NP
or	or	CC	0
other	other	JJ	0
cardiovascular	cardiovascular	JJ	B-NP
event	event	NN	I-NP
afforded	afforded	VBN	0
by	by	IN	0
peripheral	peripheral	JJ	B-NP
alpha-1	alpha-1	CD	I-NP
antagonist	antagonist	NN	I-NP
in	in	IN	0
a	a	DT	0
variety	variety	NN	0
of	of	IN	0
populations	populations	NNS	0
.	.	.	0
Differentiation	Differentiation	NNP	B-NP
of	of	IN	0
the	the	DT	0
mechanism	mechanism	NN	0
for	for	IN	0
reduced	reduced	JJ	0
protection	protection	NN	0
compared	compared	VBN	0
to	to	TO	0
diuretic	diuretic	NN	B-NP
would	would	MD	0
be	be	VB	0
interesting	interesting	JJ	0
but	but	CC	0
difficult	difficult	JJ	0
to	to	TO	0
accomplish	accomplish	VB	0
.	.	.	0
For	For	IN	0
heart	heart	NN	B-NP
failure	failure	NN	I-NP
in	in	IN	0
particular	particular	JJ	0
,	,	,	0
the	the	DT	0
increase	increase	NN	0
in	in	IN	0
symptomatic	symptomatic	JJ	B-NP
episode	episode	NN	I-NP
of	of	IN	0
CHF	CHF	NNP	B-NP
may	may	MD	0
be	be	VB	0
due	due	JJ	0
to	to	TO	0
hemodynamic	hemodynamic	VB	0
effects	effects	NNS	0
of	of	IN	0
doxazosin	doxazosin	JJ	B-NP
unmasking	unmasking	JJ	I-NP
incipient	incipient	JJ	I-NP
heart	heart	NN	I-NP
failure	failure	NN	I-NP
,	,	,	0
direct	direct	JJ	0
myocardial	myocardial	JJ	B-NP
injury	injury	NN	I-NP
,	,	,	0
or	or	CC	0
both	both	DT	0
.	.	.	0
Chronic	Chronic	JJ	B-NP
volume	volume	NN	I-NP
loading	loading	NN	I-NP
may	may	MD	0
not	not	RB	0
only	only	RB	0
unmask	unmask	VB	0
subclinical	subclinical	JJ	B-NP
ventricular	ventricular	JJ	I-NP
dysfunction	dysfunction	NN	I-NP
,	,	,	0
but	but	CC	0
may	may	MD	0
possibly	possibly	RB	0
contribute	contribute	VB	0
to	to	TO	0
worsening	worsening	VB	0
ventricular	ventricular	JJ	B-NP
function	function	NN	I-NP
over	over	IN	0
time	time	NN	0
.	.	.	0
Whatever	Whatever	JJ	0
mechanisms	mechanisms	NNS	0
were	were	VBD	0
responsible	responsible	JJ	0
for	for	IN	0
the	the	DT	0
heart	heart	NN	B-NP
failure	failure	NN	I-NP
finding	finding	NN	I-NP
in	in	IN	0
ALLHAT	ALLHAT	NNP	B-NP
,	,	,	0
the	the	DT	0
results	results	NNS	0
support	support	VBP	0
the	the	DT	0
current	current	JJ	0
national	national	JJ	0
recommendation	recommendation	NN	B-NP
to	to	TO	0
use	use	VB	0
low-dose	low-dose	JJ	B-NP
diuretic	diuretic	NN	I-NP
or	or	CC	0
beta-blocker	beta-blocker	NN	B-NP
as	as	IN	0
first	first	JJ	0
pharmacologic	pharmacologic	JJ	B-NP
treatment	treatment	NN	I-NP
line	line	NN	I-NP
agent	agent	NN	I-NP
of	of	IN	0
uncomplicated	uncomplicated	JJ	0
hypertension	hypertension	NN	0
.	.	.	0
dr	dr	NN	B-NP
competing	competing	VBG	I-NP
interest	interest	NN	I-NP
Psaty	Psaty	NNP	B-NP
was	was	VBD	0
a	a	DT	0
Merck	Merck	NNP	B-NP
/	/	NNP	I-NP
SER	SER	NNP	I-NP
Clinical	Clinical	NNP	I-NP
Epidemiology	Epidemiology	NNP	I-NP
Fellow	Fellow	NNP	I-NP
(	(	-LRB-	0
co-sponsored	co-sponsored	VBN	0
by	by	IN	0
the	the	DT	0
Merck	Merck	NNP	0
Co	Co	NNP	0
.	.	.	0
Foundation	Foundation	NNP	0
,	,	,	0
Rahway	Rahway	NNP	B-NP
,	,	,	0
NJ	NJ	NNP	B-NP
,	,	,	0
and	and	CC	0
the	the	DT	0
Society	Society	NNP	0
for	for	IN	0
Epidemiologic	Epidemiologic	NNP	B-NP
Research	Research	NNP	I-NP
,	,	,	0
Baltimore	Baltimore	NNP	0
,	,	,	0
MD	MD	NNP	0
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
a	a	DT	0
member	member	NN	0
of	of	IN	0
the	the	DT	0
Events	Events	NNP	0
Committee	Committee	NNP	0
of	of	IN	0
the	the	DT	0
HERS	HERS	NNP	0
trial	trial	NN	0
funded	funded	VBN	0
by	by	IN	0
Wyeth	Wyeth	NNP	B-NP
Ay	Ay	NNP	0
erst	erst	NN	B-NP
.	.	.	0
